RBT (Biotechnology Development JSC), a developer of innovative vaccines, has formulated an updated medium-term development strategy based on a comprehensive analysis of the current market situation and the Company's internal capabilities.
According to Igor Viktorovich Krasilnikov, CEO of RBT: "An analysis of our development experience in recent years has shown that for sustainable growth, we must focus on projects where we control the full cycle — from developing our own antigen to the finished product — and are not dependent on antigen suppliers, as is the case with influenza vaccines. This will minimize external risks and ensure the Company's technological sovereignty."
The vaccine segment remains a priority for RBT, as it is in this area that the Company possesses key competencies. RBT's portfolio includes three vaccines at an advanced stage of development. The Company is focused on the further development of these vaccines and will seek the best conditions and circumstances for their advancement.
RBT will focus, inter alia, on developing new vaccines for which it will not depend on third-party partners or antigen suppliers. The Company also plans to transition to a licensing business model involving the transfer of rights to drugs prior to obtaining marketing authorization.
RBT also plans to develop a product line of animal vaccines and medical devices based on its production facility in the Perm Region.
The influenza vaccine TetraFluBet, developed on the Company's own "Betusphere" platform, has completed Phase I and part of Phase II clinical trials. To date, the Company has not yet reached an agreement with two existing Russian manufacturers to secure long-term antigen supplies. Consequently, clinical trials may be continued if a reliable antigen supply partner emerges, including from abroad.
The coronavirus vaccine Betuvax-Cov-2 has successfully completed Phase I and Phase II clinical trials. An agreement for the transfer of technology for the production of antigens and finished products has been signed with the N. F. Gamaleya National Research Center for Epidemiology and Microbiology. The Company will continue registration actions should the epidemiological situation change or an interested partner appear.
The combined coronavirus and influenza vaccine project will be implemented subject to the conditions described above.
RBT has launched the development of a vaccine against respiratory syncytial virus (RSV). There are no RSV vaccines on the Russian market, which creates a significant market niche and generates demand for the acquisition of intellectual property rights. During R&D, several recombinant surface antigens have been obtained, and their immunogenicity is being studied.
RBT will develop a line of high-margin projects in the field of animal vaccines. This segment features a simpler regulatory pathway and will allow the Company to generate revenue more quickly.
Furthermore, RBT plans to develop contract manufacturing of medical devices at the Company's pilot production facility in the Perm Region, which will significantly reduce product time-to-market and provide the Company with financial stability.
In 2025, RBT began developing: an organ preservation solution (a medical device), a cancer vaccine for companion animals, and an adjuvant for veterinary vaccines.
RBT is a resident of Skolkovo and MedTech Technopark. RBT shares are available for trading on the Over-The-Counter (OTC) market of the Moscow Exchange. Ticker: RBTY. With the support of its industrial partner Artgen Biotech and its ecosystem, RBT is developing a platform for creating effective vaccines based on surface antigens and an original corpuscular adjuvant.